Second‐line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild‐type KRAS

The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second‐line chemotherapy in patients with irinotecan‐refractory and oxaliplatin‐naïve metastatic colorectal cancer (mCRC) harboring wild...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Sci
Prif Awduron: Hong, Yong Sang, Kim, Hwa Jung, Park, Seong Joon, Kim, Kyu‐Pyo, Lee, Jae‐Lyun, Park, Jin Hong, Kim, Jong Hoon, Lim, Seok‐Byung, Yu, Chang Sik, Kim, Jin Cheon, Baek, Ji Yeon, Kim, Sun Young, Kim, Tae Won
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2013
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657158/
https://ncbi.nlm.nih.gov/pubmed/23298313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12098
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg